Eli Lilly Shares Target Reset: What Analysts are Saying
Monday, 12 August 2024, 00:03
Eli Lilly Shares Target Reset: Analyst Insights
Leading financial institutions are adjusting their target prices for Eli Lilly shares. BMO Capital has upgraded its stock rating to outperform and raised the target from $1,001 to $1,101. Analysts noted that Lilly is experiencing successive "healthy" raises in revenue and earnings guidance, showcasing its consistent performance and resilience.
Analyst Fiscal Forecasts
- JPMorgan also raised its target, reflecting industry-wide confidence in Eli Lilly.
- The consistent revenue growth is expected to continue.
- Investors should watch for further earnings updates.
In summary, Eli Lilly's shares are on an upward trajectory guided by analyst endorsements.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.